Naricha Chirakalwasan Thailand

Dr. Naricha Chirakalwasan is a quadruple American Boards certified in Internal Medicine, Pulmonary Medicine, Critical Care Medicine, and Sleep Medicine. She is Professor of Medicine at Division of Pulmonary and Critical Care medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. She also holds the position of Associate Dean of International Affairs, Faculty of Medicine, Chulalongkorn University, Head for Respiratory Neurobiology and Sleep Assembly of Asian Pacific Society of Respirology (APSR), Head for Junior chamber committee of Asian Society of Sleep Medicine, Secretary-General for Federation of South East Asia Sleep Medicine (FSSM), and current President of Sleep Society of Thailand. Dr. Naricha Chirakalwasan published extensively in original articles and international textbooks with H-index of 22. She also received an award of “Outstanding Young Physician” in 2021 by the Royal College of Physicians of Thailand. Her research interests are on obstructive sleep apnea, NIV, insomnia, sleep health, and asthma.
Job Title
Professor
Faculty / Department / Division
Faculty of Medicine/ Department of Medicine/ Division of Pulmonary and Critical Care Medicine
Institution / Organisation
Chulalongkorn University

19 November 2026, Thursday

Time Session
08:30
13:00
Naricha Chirakalwasan Chairperson Thailand
Rashidah Yasin Chairperson Malaysia
Function Room 8, Ground Mezzanine Floor

20 November 2026, Friday

Time Session
09:30
11:00
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
  • David Halpin Speaker United Kingdom
  • Antonio Anzueto Speaker United States
  • Wisia Wedzicha Speaker United Kingdom
    This presentation will review aspects of COPD exacerbation management in the GOLD 2027 report.
  • Pang Yong Kek Speaker Malaysia
    Title: Leveraging Digital Tools in COPD Management for 2027 & Beyond Routine outpatient management of COPD faces a double deficit: up to 70% of patients make critical inhaler errors, with real-world adherence below 50%, whilst fewer than 3% complete centre-based pulmonary rehabilitation (PR). Digital healthcare addresses this through two synergistic pillars: connected smart inhalers—which enhance adherence by 22%–35% and reduce exacerbations by 17%–30% via objective flow and technique tracking—and digital therapeutics like myCOPD and Kaia COPD, which improve exercise capacity (+57.68 m 6MWD) with outcomes non-inferior to in-person PR. Remote Therapeutic Monitoring (RTM) billing frameworks establish clinical and financial viability by reimbursing multidisciplinary management of non-physiological data, medication adherence, and patient-reported outcomes. Looking toward 2027, multi-modal data fusion—integrating wearable vitals, acoustic cough biomarkers, and smart inhaler actuations—enables machine learning algorithms to forecast acute exacerbations up to 7 days ahead with 92% accuracy, aligning with recent GOLD strategy updates on early phenotypes (Pre-COPD/PRISm) and AI integration. Crucially, digital tools fail in isolation: patient engagement drops to 20% without supervision but exceeds 85% within a structured "clinician-in-the-loop" model, proving human clinical oversight remains essential for successful digital transformation.
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
    Pang Yong Kek Chairperson Malaysia
Ballroom 1, Lower Ground Floor
12:00
13:00
Sponsored by Orient EuroPharma
Mat Zuki Bin Mat Jaeb Chairperson Malaysia
Ballroom 1, Lower Ground Floor
14:00
15:00
Brendon Yee Chairperson Australia
Rozanah Abdul Rahman Chairperson Malaysia
  • Ahmad Izuanuddin Ismail Speaker Malaysia
    "Obesity and obstructive sleep apnoea (OSA) are often approached as separate clinical problems: obesity as excess weight and OSA as upper-airway obstruction. This conventional framework, however, fails to capture the complex bidirectional relationship between adiposity, sleep-disordered breathing and cardiometabolic disease. Obesity is a chronic, relapsing disease characterised by dysfunctional adipose tissue, visceral and ectopic fat accumulation, inflammation, insulin resistance and altered neuroendocrine signalling. These processes can substantially influence respiratory mechanics, upper-airway collapsibility and ventilatory control, contributing to the development and progression of OSA. Conversely, untreated OSA produces recurrent intermittent hypoxia, sleep fragmentation and sympathetic activation, promoting oxidative stress, endothelial dysfunction, hypertension, insulin resistance and broader cardiometabolic consequences. The interaction between obesity and OSA therefore creates a self-reinforcing cycle that extends far beyond the airway. This presentation explores the pathophysiological continuum linking obesity, OSA and cardiometabolic disease, and considers its implications for public health. Traditional treatment strategies, including lifestyle intervention, positive airway pressure and metabolic/bariatric surgery, remain fundamental. However, emerging pharmacological therapies offer an opportunity to address upstream biological drivers of disease. In particular, GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists represent an important evolution in obesity management, with emerging evidence demonstrating improvements in OSA severity and cardiometabolic risk alongside substantial weight reduction. The future of sleep medicine may therefore lie beyond treating airway obstruction alone. A personalised, integrated approach—combining airway therapy, obesity treatment, lifestyle intervention and cardiometabolic risk reduction—offers an opportunity to treat the patient rather than simply the apnoea. Obesity is more than a weight issue, and OSA is more than an airway problem. "
  • Yizhong Zheng Speaker Australia
    The Asia-Pacific now carries the world’s largest burden of obesity, yet obesity hypoventilation syndrome (OHS) remains under-recognised and often presents late, with acute respiratory failure. This talk examines whether current diagnostic criteria and screening tools, largely derived from non-Asian populations, serve our patients well. It explores why Asian patients may develop OHS at a lower BMI, how to identify them earlier, and how to choose and optimise PAP therapy. Finally, it considers where bariatric surgery and the new incretin-based therapies fit in a disease that PAP alone does not cure.
  • Brendon Yee Speaker Australia
    "Obstructive sleep apnoea (OSA) affects an estimated one billion adults worldwide, most of whom are overweight or obese. Yet care remains largely mechanical: diagnose, prescribe positive airway pressure (PAP), advise weight loss, and judge success by device-reported AHI. Weight-loss advice is rarely structured or followed up, and PAP, while controlling AHI and symptoms, has not been shown to alter cardiometabolic trajectory. This presentation argues for a shift in the sleep physician's role. Weight loss is disease-modifying: a 20% BMI reduction is associated with an approximately 57% fall in AHI, acting chiefly on pharyngeal collapsibility, the dominant OSA endotype. In SURMOUNT-OSA, tirzepatide reduced AHI by 20–24 events/h versus placebo over 52 weeks, with or without PAP, alongside improvements in hypoxic burden, sleepiness, blood pressure, hsCRP and patient-reported outcomes. Mediation analyses show these cardiometabolic benefits are driven predominantly by weight loss, with AHI and hypoxic-burden reduction independently mediating selected outcomes. Meta-analytic and real-world data support a class effect. A practical model of care is then outlined: patient selection, clinical and financial consent, monitoring for gastrointestinal effects, lean-mass loss and weight regain, and multidisciplinary co-management with primary care, dietetics, exercise physiology and psychology. Incretin therapy is positioned as complementary to PAP, not a replacement. Finally, Asia-Pacific realities are addressed, including variable approval and reimbursement, out-of-pocket costs, and growing cosmetic and grey-market GLP-1 use, underscoring why sleep physicians must own the medical narrative."
  • Q&A
Ballroom 3, Lower Ground Floor

21 November 2026, Saturday

Time Session
08:30
09:00
Advancing COPD Care: From Phenotypes to Targeting Treatable Traits Through Precision Medicine
Marc Miravitlles Speaker Spain
Lalitha Pereirasamy Chairperson Malaysia
"Advancing COPD Care: From Phenotypes to Targeting Treatable Traits Through Precision Medicine Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition characterised by substantial variability in clinical presentation, underlying biological mechanisms, disease trajectory and response to treatment. This heterogeneity has challenged the traditional approach of classifying patients according to fixed clinical phenotypes and applying largely uniform treatment strategies. Increasing evidence supports a shift towards precision medicine, in which treatment decisions are guided by the identification of individual, measurable and clinically relevant treatable traits. The concept of treatable traits represents an evolution from phenotype-based classification towards a multidimensional assessment of the patient. Rather than assigning patients to mutually exclusive categories, this approach recognises that several clinically relevant traits may coexist within the same individual and may change over time. These traits can encompass pulmonary characteristics, such as airflow limitation, hyperinflation, emphysema, chronic bronchitis, bronchiectasis and chronic bronchial infection, as well as systemic and extrapulmonary features including cardiovascular disease, frailty, osteoporosis, skeletal muscle dysfunction, anxiety and depression, and physical inactivity. Importantly, treatable traits should not simply describe disease characteristics; they should identify clinically relevant abnormalities for which an effective intervention is available. This distinction is particularly relevant as therapeutic options for COPD continue to expand. Blood eosinophil counts, for example, can help identify patients who are more likely to benefit from inhaled corticosteroids and, more recently, from targeted biologic therapies. Similarly, frequent exacerbations, chronic bronchial infection, mucus hypersecretion, pulmonary hyperinflation and physical inactivity may each require different therapeutic strategies, ranging from pharmacological treatment to pulmonary rehabilitation, airway clearance, antimicrobial approaches or interventions aimed at reducing hyperinflation. The emergence of biologic therapies targeting specific inflammatory pathways represents an important step towards precision treatment in COPD. However, precision medicine should not be equated with precision pharmacotherapy. Its broader objective is to integrate clinical characteristics, biomarkers, imaging, physiological measurements, comorbidities, environmental exposures and patient-reported outcomes to construct an individualised disease profile and select interventions according to the dominant treatable traits. Future COPD management will therefore require dynamic rather than static patient characterisation. Treatable traits may evolve with disease progression, exacerbations, treatment and ageing, making repeated assessment essential. Digital health, artificial intelligence, multi-omics and increasingly accessible biomarkers may further improve phenotyping and prediction of treatment response. The transition from phenotypes to treatable traits offers an opportunity to move beyond a one-size-fits-all model of COPD care. The challenge now is to determine which traits are clinically meaningful, how they should be identified and prioritised, and whether treating them translates into better outcomes. Precision medicine in COPD should ultimately be judged not by the sophistication of patient classification, but by its capacity to deliver more effective, personalised and clinically meaningful care."
Ballroom 3, Lower Ground Floor
09:00
09:30
Translational Research on the Development of Antifibrotic Drugs for Pulmonary Fibrosis and Lung Cancer
Yasuhiko Nishioka Speaker Japan
Lalitha Pereirasamy Chairperson Malaysia
Ballroom 3, Lower Ground Floor
09:30
10:30
Tan Jiunn Liang Chairperson Malaysia
Yasutaka Nakano Chairperson Japan
  • Asiah Kassim Speaker Malaysia
    Both Technical Standards of Spirometry and Lung Volume by ATS/ERS in 2019 and 2023 highlighted the importance of the equipment, quality assurance of the equipment and training of operator handling the equipment and the test. The technique of spirometry prefers both expiratory and inspiratory, calculation of BEV, acceptability of FEV1 and FVC and not the maneuver, repeatability and quality spirometry and lung volume values. The changes require more trained operator and time for the test to be done with a new equipment for measurement. The clinical application of the usable FEV1 and FVC values for interpretation is helpful in certain group of patients like children. However, the new definition of bronchodilator responsiveness based on predictive value is not adapted by GINA or GOLD 2026 as both definitions in 2005 and 2022 is still comparable.
  • Susumu Sato Speaker Japan
    "Beyond Spirometry: Integrating Morphometry and Mechanics for Precision Medicine Although spirometry remains fundamental to respiratory assessment, conventional indices alone do not fully account for the substantial heterogeneity observed in chronic respiratory diseases. Patients with comparable airflow limitation may exhibit marked differences in symptoms, gas exchange impairment, functional capacity, prognosis, and treatment response. This underscores the need to incorporate additional morphological and physiological dimensions into disease assessment. Flow–volume curves contain valuable yet underutilized information beyond FEV₁ and FEV₁/FVC, including mid- and late-expiratory flows, inspiratory–expiratory relationships, and curve-shape or area-based metrics. When interpreted with careful attention to effort dependence, volume dependence, and technical quality, these features may provide further insight into underlying disease mechanisms. Recent developments in imaging-based morphometry have broadened phenotyping beyond the traditional assessment of emphysema severity. Previous research demonstrated that computed tomography (CT)-derived airway wall dimensions and emphysema provide complementary information regarding pulmonary function, supporting the view that airway and parenchymal abnormalities represent distinct yet interacting contributors to airflow limitation. More recent studies suggest that different CT phenotypes carry distinct clinical implications, with differential associations with longitudinal decline in FEV1 and diffusing capacity, as well as prognosis. In addition, airway structural abnormalities, including airway wall thickening and mucus plugging, may be linked not only to airflow limitation and adverse outcomes, but also to specific disease backgrounds such as a history of asthma. Moreover, the scope of imaging-based morphometry may extend beyond the airways and parenchyma to include extrapulmonary and vascular features, such as muscle dysfunction, thereby providing additional functional and prognostic insights. These findings support an integrated framework in which respiratory disease is understood through the interplay between structural abnormalities and their mechanical consequences. In this presentation, I will discuss how integrating imaging-based morphometry with spirometry and broader physiological assessment may move respiratory medicine beyond a spirometry-centered paradigm toward more precise phenotyping, improved risk stratification, and individualized patient care. "
  • Nguyen Van Tho Speaker Vietnam
    Accurate interpretation of lung function is very important for managing respiratory diseases. Diagnosis and classification of the severity of abnormal lung function tests depend on the reference equations used. The Global Lung Function Initiative (GLI) 2021 reference equations were derived from a large representative sample across the entire age range and different ethnic groups using updated standardized techniques of lung function measurements. However, for the Asia-Pacific region—characterized by immensly different genetic, race, environmental, lifespan and varying healthcare infrastructures—using GLI 2021 reference equations presents diagnostic challenges. Implementation of GLI 2021 in Asian populations requires careful validation against existing "Asian-specific" norms. Research indicates that the application of universal equations can alter the "Lower Limit of Normal" (LLN), potentially impacting the diagnosis of restrictive or obstructive patterns or the impairement of lung diffusion capacity in airways and interstitial lung diseases. The GLI 2021 do not include individual data from all populations in the Asia-Pacific region and do not explicitly consider the factors that may contribute to the observed differences in lung function between populations. GLI DLCO equations and GLI static lung volumes are currently based on measurements predominantly from individuals of European ancestry due to insufficient reference data from other populations. In addition, some institutions in the Asia-Pacific region continue using the old models of lung function tests, which are not suitable for GLI 2021. This presentation will highlight some challenges and potential pitfalls when implementing GLI 2021 in the diverse Asia-Pacific region.
  • Q&A
Ballroom 1, Lower Ground Floor
11:00
12:30
Allen Widysanto Chairperson Indonesia
Rashidah Yasin Chairperson Malaysia
  • Naricha Chirakalwasan Speaker Thailand
  • Kah-Lin Choo Speaker Singapore
    Toward Personalised Non-PAP Therapy for Obstructive Sleep Apnoea While positive airway pressure (PAP) remains the gold standard treatment for obstructive sleep apnoea (OSA), long-term compliance is frequently limited by patient intolerance. Emerging insights into the pathophysiology of OSA reveal that the condition is not solely driven by anatomical airway collapse; rather, it is governed by four distinct endotypes that include three non-anatomical endotypes such as poor upper airway muscle responsiveness, low respiratory arousal threshold, and high loop gain (ventilatory control instability). This paradigm shift paves the way for precision medicine and targeted, non-PAP therapeutic strategies tailored to individual physiological profiles. This lecture will review recent advances in non-PAP therapeutic modalities mapped to specific OSA endotypes, examine clinical trial evidence, and address current challenges and future directions in clinical phenotyping and personalized care. Strategies include anti-obesity interventions such as dual GIP/GLP-1 receptor agonists and structural stabilization through hypoglossal or ansa cervicalis nerve stimulation, pharmacological neuromuscular stabilization, loop gain modulation and arousal threshold management. Personalising non-PAP therapy based on individual pathophysiological traits offers a promising paradigm for patients who refuse or are intolerant to PAP. Future clinical success relies on validating automated computational phenotyping tools within routine diagnostic workflows, standardizing prediction thresholds across diverse global populations, and establishing outcome-focused trials linked to hard clinical endpoint.
  • Winfried J. Randerath Speaker Germany
  • Q&A
Ballroom 2, Lower Ground Floor
12:30
13:30
Sponsored by AstraZeneca
Azza Omar Chairperson Malaysia
Ballroom 2, Lower Ground Floor

22 November 2026, Sunday

Time Session
08:30
09:00
The Future of Respiratory and Critical Care: Scaling The 4P Approach To Clinical Trials
Michelle Gong Speaker United States
Chong Kin Liam Chairperson Malaysia
The 4P approach in medicine includes prevention, prediction, personalization and patient participation. This 4P approach is already being scaled to critical care clinical trials. Prevention for critical illness exist at different levels across the continuum of critical illness The new global ARDS definition, which now permits earlier enrolment of non-intubated patients allows for trials aimed at prevention of intubation and indeed, recent "positive" trials have consequently enrolled hospitalized patients before mechanical ventilation. Because most patients never develop the disease, prevention demands prediction which serves as enrichment strategies in clinical trials to identify patients for trial enrollment. Two enrichment strategies include prognostic enrichment (selecting for higher event rates, e.g. severe ARDS with PaO₂/FiO₂ < 150 mmHg) and predictive enrichment (selecting patients more likely to respond biologically). Predictive enrichment also leads to precision medicine which is already occurring in ARDS trials. The final 4P is patient participation, covering patient-reported outcomes in post-intensive care syndrome and equity in enrollment into clinical trial participation.
Ballroom 3, Lower Ground Floor
09:00
10:30
Rus Anida Awang Chairperson Malaysia
  • Kate Chan Speaker Hong Kong
  • Naricha Chirakalwasan Speaker Thailand
  • Albert M. Li Speaker Hong Kong
    Childhood obstructive sleep apnoea (OSA) is a common condition linked to a range of complications, including neurocognitive and behavioural impairments, reduced quality of life, and elevated metabolic and cardiovascular risks. Adenotonsillectomy (AT) remains the first-line treatment, offering proven benefits across these domains. Timely diagnosis is therefore essential for early intervention and improved outcomes. Polysomnography (PSG) is the gold standard for diagnosing OSA. However, limited access leads to longer waiting periods. Moreover, the requirement for an overnight hospital stay can be particularly challenging for children. Given current limitations, there is a pressing need for a validated, user-friendly diagnostic tool to enable early and accurate identification of paediatric OSA. Recent research has shifted focus toward nocturnal hypoxaemia. A novel metric, the hypoxic burden (HB), first introduced by Azarbarzin et al., has shown superior predictive value for cardiovascular mortality than the apnoea-hypopnoea index (AHI) in adults. Despite its promise, HB has been criticised for its computational complexity. A more streamlined and accurate alternative, the oxygen desaturation burden index (OBI), has since emerged. This severity metric accounts for both the depth and duration of oxygen desaturations without requiring respiratory event scoring. Importantly, OBI can be derived from simple overnight oximetry, making it a more accessible and cost-effective option for home-based assessments. In this presentation, the speaker will discuss the usefulness of OBI and his research on using this parameter in interventional studies and in assessing cardiovascular complications in children with OSA.
  • Dg Zuraini Sahadan Speaker Malaysia
    From Lab to Wrist: The Emerging Role of Wearables in Paediatric Sleep Medicine Overnight in-laboratory polysomnography (PSG) has long been the gold standard for diagnosing paediatric sleep-disordered breathing. However, long waiting lists, high costs, and the distress of overnight hospital stays for young children have limited patient access. Recent landmark validation studies highlight that specialized paediatric-trained deep learning algorithms—specifically dual-stream local-global Long Short-Term Memory (LSTM) networks which can process raw wrist movement and heart rate signals to achieve 95% ROC-AUC accuracy in classifying sleep and wakefulness. Unlike traditional adult models or older mathematical scoring methods, these paediatric AI classifiers eliminate proportional bias and estimate total sleep duration within minutes of laboratory gold standards. Furthermore, systematic evidence across 62 portable sleep monitoring trials reveals that multi-channel home polygraphy and AI-assisted pulse oximetry offer specificities up to 100% for ruling in severe paediatric Obstructive Sleep Apnea (OSA). This allows clinicians to fast-track children with adenotonsillar hypertrophy for urgent surgical adenotonsillectomy without unnecessary laboratory delays. By combining wrist movement sensors with optical heart rate tracking and paediatric deep learning, we can evaluate children over multiple nights in their natural home environment. This transition from lab to wrist bridges the gap between cutting-edge technology and accessible child healthcare.
  • Q&A
Ballroom 2, Lower Ground Floor